October 26, 2022
FDA: Class I recall of Jiangsu Well Biotech COVID-19 Ag Rapid Test
Editor's Note
The Food and Drug Administration (FDA) on October 12 identified the recall of Jiangsu Well Biotech’s COVID-19 Ag Rapid Test Devices as Class I, the most serious.
The recall was initiated because the tests were distributed to US customers without authorization, clearance, or approval from the FDA.
No complaints, injuries, or deaths have been reported.
Distribution dates were July 23, 2021 to January 23, 2022.
Free Daily News
- Healthcare M&A faces tighter review as FTC retains guidelines
- Healthcare giants prioritize shareholder payouts over patient care
- Texas abortion ban linked to spike in pregnancy complications, maternal death
- AI streamlines documentation, frees time for nurses at Cedars-Sinai surgical unit
- Study identifies potential non-surgical treatment for inguinal hernias
- Rural hospital closures remain a growing concern despite slight financial improvement
- Session: Hoisting the Sails—Winning Strategies for Growing Service Lines in an ASC
- Session: Riding the Wave—Considerations to Making Anesthesia Profitable in Today's Labor Market
- Session: Surfs Up—Rolling Out the OAS CAHPS Survey
- Montana legislators' prior authorization reform push mirrors national trends
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement